Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
~~~~5~~
DESCRIPTION
THERAPEUTIC AGENT FOR SKIN OR CORNEAL DISEASE
TECHNICAL FIELD
The present invention relates to a therapeutic agent
for skin or corneal diseases, and more specifically to a
therapeutic agent for skin or corneal diseases, which
contains CPB-I or recombinant CPB-I as an active ingredient
and is useful for treating a skin or corneal disease such as
a wound or psoriasis.
BACKGROUND ART
There have hitherto been provided a number of
substances having a therapeutic effect on skin and corneal
diseases, in particular, wounds. For example, growth
factors (BIO/Technology, 135-140, 1985) such as an epidermal
growth factor (EGF) (Exp. Cell Res., 164, 1-10, 1986), acid
and basic fibroblast growth factors (acid and basic FGFs)
(J. Surg. Res., 45, 145-153, 1988), transforming growth
factors (TGF-a and TGF-~) (Japanese Patent Application
Laid-Open No. 167231/1990; Science, 233, 532-534, 1986) and
insulin-like growth factors (IGF-I and IGF-II), adhesion
factors such as fibronectin, laminin and vitronectin (Ann.
Rev. Biochem., 52, 961, 1983), and chemical substances such
as retinoids and analogous compounds thereof (Am. J.
1
2~9~~2~
Ophthalmol., 95, 353-358, 1983; Ann. Ophthal., 19, 175-180,
1987) have been known. The healing process of the skin
wound is accompanied by granulation tissue formation,
angiogenesis and re-epithelization. In these processes,
fibroblasts, vascular endothelial cells and epidermal cells
(keratinocytes) proliferate and migrate, respectively. The
above-mentioned factors and other chemical substances have
been known to be effective to the skin healing.
The healing process of the epithelia, parenchyma and
endothelia of the cornea is accompanied by the migration and
proliferation of epithelial cells, the phagocytosis of waste
matter and the production of extracellular matrix by
parenchymal cells, and the migration of endothelial cells,
respectively.
In recent years, damages of endothelial cells have
become recognized after cataract surgery, keratoplasty and
wearing of contact lenses. Therefore, the importance of the
endothelial cells has been pointed out. Human endothelial
cells are said not to proliferate or to be hard to do. In
their healing process, their migration and adhesion might be
important. Up to the present, it has been reported that
use of rabbit cultured endothelial cells which has
proliferating ability revealed the fact that EGF and FGFs
promote their proliferation. However, any effective remedy
2
~~~~5~~
has not been yet reported. There is hence a demand for
development of such an agent as promote the migration and
adhesion of the endothelial cells.
On the other hand, as clinical pictures of skin
diseases, in particular, psoriasis which is a chronic skin
disease, there have been leukocyte infiltration (J. Invest.
Dermatol., 68, 43-50, 1977), the hyperplasia of epidermis
(J. Invest. Dermatol., 50, 254-258, 1968) and aberrant
terminal differentiation (J. Invest. Dermatol., 70, 294-297,
1978), and as biochemical findings, there have been
known, from the investigation on the mouse skins applied
with a phorbol ester (TPA) which is a carcinogen, exhibiting
psoriasis-like findings, the activation of protein kinase C
(PKC) (J. Invest. Dermatol., 93, 379-386, 1989), increase in
release of arachidonic acid and prostaglandin (Biochem.
Biophys. Res. Commun., 92, 749-756, 1980), induction of
ornithine dehydrogenase and transglutaminase activity
(Cancer Res., 39, 4183-4188, 1979; Biochem. Biophys. Res.
Commun., 97, 700-708, 1980) and increase in interleukin 1
(J. Invest. Dermatol., 88, 499A, 1987).
Steroid ointments and PWA therapy have been used in
local treatment for psoriasis, and dietetic therapy, vitamin
D2, vitamin B12, etretinoids, etc. in general treatment. In
recent years, TGF-~ having an antiproliferative effect on
keratinocytes (Japanese Patent Application Laid-Open No.
3
~09~~2fl
167231/1990) and cyclosporin A having an antiinflammatory
effect (JAMA, 256, 3110-3116, 1986) have also been studied
as therapeutic agents for psoriasis. However, action
mechanisms thereof have not yet been clear.
Although the above-mentioned factors and chemical
substances have been known as remedies for skin and corneal
diseases such as wounds and psoriasis, their effects have
been yet far from satisfactory.
It is considered to supplementarily use an agent having
the different action mechanism in order to enhance the
effect of the conventional agent, heal promptly and to cure
completely in the therapy of a skin or corneal disease.
However, any satisfactory agent has not been yet provided.
Therefore, it is an object of this invention to provide
a therapeutic agent for skin or corneal diseases, which has
an action mechanism different from that of the conventional
agent and is excellent in therapeutic effect.
In view of the foregoing circumstances, the present
inventors have carried out an extensive investigation. As a
result, it has been found that CPB-I, which is an
anticoagulant, is excellent in therapeutic action on skin
and corneal diseases, and its action mechanism is different
from that of the conventional agent, leading to completion
4
24~'~~~?~
of the present invention.
DISChOSURE OF THE INVENTION
The present invention is directed to a therapeutic
agent for skin or corneal diseases containing CPB-I or
recombinant CPB-I as the active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. 1(1)-(3) are diagrams respectively illustrating
the experimental results as to effect on the migration of
HNEK, HUVEC and Flow 2000 in Experimental Example 1.
FIGS. 2(1)-(3) are diagrams respectively illustrating
the experimental results as to effects on the adhesion of
Flow 2000, HUVEC and HNEK in Experimental Example 2.
FIG. 3 is a diagram illustrating the experimental
results as to an effect on the PKC activity in Experimental
Example 4.
FIG. 4 is a diagram illustrating the experimental
results as to an effect on the PKC activity in Experimental
Example 5.
BEST MODE FOR CARRYING OUT THE INVENTION
CPB-I which is an active ingredient in the therapeutic
agent for skin or corneal diseases according to the present
invention is an ubiquitous protein in the body, including
the human placenta and secretary fluids CChem. Pharma. Bull,
38, 1957-1960, 1990), exists in cytosol fraction in the
cells and has physiological activities such as anticoagulant
activity.
CPB-I can be extracted from human or animal organs
(Japanese Patent Application Laid-Open No. 174023/1987).
The thus obtained CPB-I has the following properties.
(1) Molecular weight (SDS-polyacrylamide gel electro-
phoresis, in a reducing state):
34,000 ~ 2,000
(2) Isoelectric point (isoelectric column electro-
phoresis using an ampholite):
4.7 + 0.1
(3) Stability:
(a) Deactivated by a heat treatment at 50°C for 30
minutes
(b) Stable at pH 4-10
(c) Stable at 37'C for 30 minutes in a plasma
(4) Action on blood coagulation system:
(a) Extending recalcification coagulation time
(b) Extending prothrombin time
(c) Extending activated partial thromboplastin
time
(5) Amino acid analysis:
6
2096520
By amino acid analysis, it is recognized that aspartic
acid, threonine, serine, glutamic acid, proline, glycine,
alanine, cystine, valine, methionine, isoleucine, leucine,
tyrosine, phenylalanine, histidine, lysine and arginine
exist.
CPB-I can be developed in Escherichia coli by a gene
recombination technique making use of a gene fragment that
codes for human or animal CPB-I (Japanese Patent Application
Laid-Open No. 20095/1989). CPB-I obtained by the gene
recombination technique in the above-described manner
(hereinafter referred to as "recombinant CPB-I") has the
following amino acid sequence:
Ala-Gln-Val-Leu-Arg-Gly-Thr-Val-Thr-Asp-Phe-Pro-Gly-Phe-Asp
Glu-Arg-Ala-Asp-Ala-Glu-Thr-Leu-Arg-Lys-Ala-Met-Lys-Gly-Leu
Gly-Thr-Asp-Glu-Glu-Ser-Lle-Leu-Thr-Leu-Leu-Thr-Ser-Arg-Ser
Asn-Ala-Gln-Arg-Gln-Glu-Ile-Ser-Ala-Ala-Phe-Lys-Thr-Leu-Phe
Gly-Arg-Asp-Leu-Leu-Asp-Asp-Leu-Lys-Ser-Glu-Leu-Thr-Gly-Lys
Phe-Glu-Lys-Leu-Ile-Val-Ala-Leu-Met-Lys-Pro-Ser-Arg-Leu-Tyr
Asp-Ala-Tyr-Glu-Leu-Lys-His-Ala-Leu-Lys-Gly-Ala-Gly-Thr-Asn
Glu-Lys-Val-Leu-Thr-Glu-Ile-Ile-Ala-Ser-Arg-Thr-Pro-Glu-Glu
Leu-Arg-Ala-Ile-Lys-Gln-Val-Tyr-Glu-Glu-Glu-Tyr-Gly-Ser-Ser
Ler-Glu-Asp-Asp-Val-Val-Gly-Asp-Thr-Ser-Gly-Tyr-Tyr-Gln-Arg
Met-Leu-Val-Val-Leu-Leu-Gln-Ala-Asn-Arg-Asp-Pro-Asp-Ala-Gly
Ile-Asp-Glu-Ala-Gln-Val-Glu-Gln-Asp-Ala-Gln-Ala-Leu-Phe-Gln
7
2096520
Ala-Gly-Glu-Leu-Lys-Trp-Gly-Thr-Asp-Glu-Glu-Lys-Phe-Ile-Thr
Ile-Phe-Gly-Thr-Arg-Ser-Val-Ser-His-Leu-Arg-Lys-Val-Phe-Asp
Lys-Tyr-Met-Thr-Ile-Ser-Gly-Phe-Gln-Ile-Glu-Glu-Thr-Ile-Asp
Arg-Glu-Thr-Ser-Gly-Asn-Leu-Glu-Gln-Leu-Leu-Leu-Ala-Val-Val
Lys-Ser-Ile-Arg-Ser-Ile-Pro-Ala-Tyr-Leu-Ala-Glu-Thr-Leu-Tyr
Tyr-Ala-Met-Lys-Gly-Ala-Gly-Thr-Asp-Asp-His-Thr-Leu-Ile-Arg
Val-Met-Val-Ser-Arg-Ser-Glu-Ile-Asp-Leu-Phe-Asn-Ile-Arg-Lys
Glu-Phe-Arg-Lys-Asn-Phe-Ala-Thr-Ser-Leu-Tyr-Ser-Met-Ile-Lys
Gly-Asp-Thr-Ser-Gly-Asp-Tyr-Lys-Lys-Ala-Leu-Leu-Leu-Leu-Cys
Gly-Glu-Asp-Asp.
In addition to Escherichia coli, recombinant CPB-I can
also be produced by using yeast (Japanese Patent Application
Laid-Open No. 219875/1990).
The thus-obtained CPB-I and recombinant CPB-I have
activity for healing the skin and corneal diseases.
For example, an investigation of the therapeutic action
of CPB-I or recombinant CPB-I on a wound repair using
cultured cells derived from human skin showed
that it promotes the migration of keratinocytes, and has, as
an adhesion factor, an activity comparable or equal to that
of fibronectin on the keratinocytes and vascular endothelial
cells. In the case that CPB-I or recombinant CPB-I is used
for a wound in the rat skin, the regeneration of epidermis
and granulation tissue is also promoted.
8
It is suggested from these results that CPB-I and
recombinant CPB-I promote re-epithelization in wound repair,
and in its turn facilitate angiogenesis and regeneration of
granulation tissue, thereby exhibiting the overall promotion
of healing. It is also considered that their action
mechanisms are different from that of the conventional
agent.
Since the conventional remedies are also used in the
corneal wound in addition to the skin wounds, and the cornea
is similar to the skin even in the kind of embryologically
organized cells (epithelial, parenchymal and endothelial
cells), CPB-I can be expected to act on the corneal wound.
Therefore, the effect of CPB-I on migration and
adhesion was investigated using cultured endothelial cells
of the rabbit cornea. In the migration, an effect
comparable to those of EGF and fibronectin was recognized,
and combination use with EGF enhanced the effect. It was
hence suggested that its action mechanism is different from
that of EGF. Although its effect on the adhesion is no
match for that of fibronectin, it was recognized to have the
activity of an adhesion factor. From these results, CPB-I
can be expected to maintain the function of corneal
endothelial cells by adding it to a preservative liquid for
a cornea block of a donor upon keratoplasty, protect
endothelial cells of the cornea or cure its wound by adding
9
~a9~~~~~1
it to an intraocular irrigating solution or an infusion
solution to an anterior chamber upon cataractous surgery,
and in its turn promote the wound healing of the cornea.
In the meantime, the pathogenesis of psoriasis which is
a chronic skin disease is not yet clear, so that there is no
model animals therefor. It has however been known that the
mouse skin applied TPA which is a carcinogen has psoriasis-
like inflammation from the side view of biochemistry,
activation of PKC, increase in release of arachidonic acid
and prostaglandin, induction of ornithine dehydrogenase,
transglutaminase activity and increase in interleukin 1.
Although the keratinocytes are cultured in the presence of
calcium in a low concentration (< 0.15 mM), it is also known
that the keratinocytes differentiate within several days if
the concentration of calcium is increased to at least 1 mM
(Cell, 19, 245-254, 1980). It is also known that at this
time, the concentration of intracellular calcium increases
(Carcinogenesis, 10, 777-780, 1989), and desmosomes then
form in several hours (Cell, 19, 245-254, 1980). TPA is
known to activate PKC (J. Invest. Dermatol., 92, 175-178,
1989), and to promote only a part of cultured keratinocytes
to differentiate while promoting the residual cells to
proliferate (Cancer Res., 42, 2344-2349, 1982). This action
is consistent with that on the mouse skin.
Therefore, the therapeutic actions of CPB-I and
recombinant CPB-I on psoriasis were investigated using
cultured human keratinocytes from the side view of biology.
More specifically, the actions of CPB-I or recombinant CPB-I
on the intracellular PKC activity and PKC activation by TPA
were investigated. As a result, it was found that these
agents reduce the PKC activity in cytosol fraction and
suppress PKC activation by TPA.
The action mechanisms of CPB-I and recombinant CPB-I in
the treatment of psoriasis have not been fully elucidated.
However, taking account the fact that the conventional
therapeutic agent for psoriasis or Cyclosporin A has no
influence on the PKC activity (J. Invest. Dermatol., 93,
379-386, 1989), it is conjectured that they have an action
mechanism different from that of the conventional agent.
Therefore, it is expected that the treatment with CPB-I
and recombinant CPB-I alone might be effective for a skin or
corneal disease, and, furthermore, treatment combined with
other therapeutic agents might be more effective.
CPB-I and recombinant CPB-I may preferably be contained
in a proportion ranging from 0.01 to 100 mg, in particular,
from 1 to 100 mg per 100 g of the therapeutic agent for skin
or corneal diseases according to the present invention.
No particular limitation is imposed on the form of the
11
~~~6~~~
therapeutic agent for skin and corneal diseases according to
the present invention so long as it is in common use in
pharmaceutical preparations. The agent may be in the form
of a buffer solution, gel, cream, ointment, ophthalmic
solution, ophthalmic ointment or the like.
CPB-I may be added to, for example, EP-II (product of
Kaken Pharmaceutical Co., Ltd.) being in use at present as a
preservative solution for a cornea block of a donor. In
addition, CPB-I may be added to, for example, Opegard MA
(product of Senju Seiyaku K.K.), BSS (product of Alcon
Labs., Inc.), BSS Plus (product of Alcon Labs., Inc.) or an
aqueous solution of hyaluronic acid, which are in use at
present as an intraocular perfusion solution or a solution
for infusing in an anterior chamber.
EXAMPLES
The present invention will hereinafter be described in
more detail by the following experimental examples and
examples.
Incidentally, in the experimental examples and
examples, we have studied using CPB-I or recombinant CPB-I,
obtained in accordance with Example 1 in Japanese Patent
Application Laid-Open No. 174023/1987 or Example 4 in
Japanese Patent Application Laid-Open No. 20095/1989,
respectively.
12
~o~~ j~Q
Experimental Example 1 Action on extension:
(1) Human normal epidermal keratinocytes (HNEK), (2)
human normal vascular endothelial cells (HWEC), (3) fetal
human lung-derived fibroblasts (Flow 2000) and (4) rabbit
corneal endothelial cells [cultured from the cornea of New
Zealand white rabbit in accordance with the method of
Raymond G. M. et al. (Raymond G. M. et al., Invest.
Ophthalmol. Vis. Sci., 27: 474-479 (1986))] were incubated
to be confluent, respectively, in a keratinocyte cell growth
medium (KGM) (product of Clonetics Company) containing a
bovine pituitary extract (BPE), an endothelial cell growth
medium (EGM) (product of Clonetics Company), an Eagle's
minimum essential medium (E'MEM) containing 10~ of fetal
calf serum (FCS) and Medium 199 containing 10~ of FCS and 10
ng/ml of mouse EGF. Cells on the opposite side from the
center line were scraped out by a rubber policeman. After
each well was washed with its corresponding medium, the
medium was replaced by a medium containing CPB-I obtained in
Referential Example 1. On that day and after two days, each
well was recorded through a microscope. On the recorded
image, distances migrated from wound edge in HNEK and the
rabbit corneal endothelial cells, and cell numbers existing
within certain distances from wound edge in HWEC and Flow
2000 were measured or determined. The results as to the
rabbit corneal endothelial cells and the results as to the
13
~09~5~0
other cells are shown in Table 1 and FIG. 1, respectively.
Table 1: Effect on Migration of rabbit corneal
endothelial cells
Distance from woundedge
(u
m)
(mean E., n = 4)
S.
____-Cont~ol ______________ 6g + 11
*
(5 ng/ml) 170 8
EGF
EGF (50 ng/ml) 218 36
EGF (500 ng/ml) 229 16
CPB-I (10 a g/ml) 138 34
CPB-I (50 ~ g/ml) 183 27
CPB-I (100 ~ g/ml) 201 30
FN*2 (10 ~ g/ml) 111 38
FN (50 ~ g/ml) 142 60
FN (100 ~ g/ml) 222 25
EGF (5 ng/ml~-________ 170 ~ 8
EGF + CPB-I (10 ~ g/ml) 166 ~ 14
EGF + CPB-I (50 a g/ml) 242 ~ 30
EGF + CPB-I (100 a g/ml) 253 ~ 16
*1: Mouse EGF
*2: Rabbit plasma fibronectin [prepared in accordance
with Int. J. Cancer, 20, 1-5 (1977)]
From the above results, it was recognized that CPB-I
has an effect of migrating the corneal endothelial cells
and, can also be used in combination with EGF. It is also
found from FIG.l that CPB-I allows the migration of HNEK,
HWEC and Flow 2000.
Experimental Example 2 Effect on adhesion:
HNEK, HWEC, Flow 2000 and rabbit corneal endothelial
cells, which were suspended in KGM, MCDB 151, E'MEM and
Medium 199, respectively, were separately plated (1000
14
cells/well) on the well coated with CPB-I obtained in
Referential Example 1, fibronectin or bovine serum albumin
(BSA). Upon predetermined elapses of time, cells not
adhering to each well were washed off with a Hanks' buffer
solution, and the adherent cells were fixed with a 20~
neutral buffered formalin fixative and then stained with
hematoxylin and eosin (H.E.), thereby counting the number of
adherent cells through a microscope. The results as to the
rabbit corneal endothelial cells and the results as to the
other cells are shown in Table 2 and FIG. 2, respectively.
Table 2: Effect on adhesion of rabbit corneal
endothelial cells
Number of Adherent Cells
Time ________ ________ ____________
(hr) BSA*3 FN*4 CPB-I
0.5 32 ~ 5 261 + 15 108 + 8
1 47 _+ 2 297 _+ 10 109 ~ 10
2 133 + 8 312 + 8 195 + 13
*3: Bovine serum albumin
*4: Rabbit plasma fibronectin
Table 2 and FIG. 2 indicate that CPB-1 certainly acts
on cellular adhesion.
Experimental Example 3 Effect on wound of rat:
blister male rats aged 8 weeks were anesthesized with
ether, and their dorsal hairs were shaved with an electric
2~9~~~~
razor. Thereafter, a full-thickness round wound having a
diameter of 9 mm was prepared using a trepane (Natsume
Seisakusho). From the operation day, a phosphate buffer
solution (PBS) containing CPB-I (PBS in a control group) was
applied one time in the morning and one time in the evening
each in an amount of 50 ~1 to the wounded site for 4 days.
Upon the 4th day after wounding, the wounds were exercised
and fixed in a 10~ neutral buffered formalin. The tissue
was embedded in paraffin, sectioned across the central part
of the wound and stained with a hematoxylin and eosin
(H.E.). The section was photographed through a microscope
and the length of epidermal regeneration was measured,
magnifying at x 23. Area of a granulation tissue was
estimated copying the photograph enlarged 23 times, cutting
off a site of granulation tissue and then weighing it. The
number of capillary in the granulation tissue was counted
through the microscope. The results are shown in Table 3.
16
2096520
Table 3
Number of Epidermal Granulation Number of
Treatment Specimens regeneration Tissue Area Capillary
(n) vess is
mm mm2 n/mm~
( ( (
) ) )
Control
group 10 1.660+0.114 4.36+0.52 110.39.0
CPB-I
(l0~cg/rat)10 1.747+0.140 5.180.37 97.37.9
CPB-I
(100u g/rat)9 +0.160 5.260.31 103.1_+12.3
2.198
_
(p < 0.01)
Table 3 indicates that CPB-I promotes the regeneration
of epidermis, granulation and angiogenesis.
Experimental Example 4 Effect on PKC activity:
70-80g Confluent of HNEK was replaced to a KGM medium
containing CPB-I, and incubated for 30 minutes. After
incubation, cells were harvested, homogenized, fractionated
to cytosol fraction and membrane fraction, and then measured
their PKC activity using a PKC assay system (manufactured by
Amersham Company). Each value in Fig. 3 indicates the mean
value of three experiments. FIG. 3 indicates that CPB-I
decreases the PKC activity.
Experimental Example 5 Effect on PKC activation:
70-80~ Confluent of HNEK was replaced to a KGM medium
17
ng/ml of mouse EGF. Cells on the opposite side from the
~Q~6~~~
separately containing CPB-I (10 ~ g/ml) obtained in
Referential Example 1. After 30 minutes incubation, 10
ng/ml TPA was added thereto, and further incubated for the
indicated periods of time. The cells were harvested,
homogenized, fractionated to cytosol fraction and membrane
fraction, and then measured the PKC activity using a PKC
assay system (manufactured by Amersham Company) (FIG. 4).
FIG. 4 indicates that CPB-I suppresses the
activation of PKC by TPA.
Example 1:
A creamy preparation having the following composition
was produced according to a standard method.
(Composition)
CPB-I 1-100 mg
White petrolatum 4.0 g
Light liquid paraffin 6.0 g
Cetyl alcohol 3.0 g
Stearyl alcohol 3.0 g
Isopropyl myristate 4.0 g
Emulsifier 3.5 g
Purified water To 100.0 g
A similar creamy preparation was also produced
using
recombinant CPB-I in place of CPB-1.
18
2096~~Q
Example 2:
A gel preparation having the following composition was
produced according to a standard method.
(Composition)
CPB-I 1-100 mg
Carboxyvinyl polymer 0.5 g
Methyl cellulose 0.2 g
Glycerol 5.0 g
Sodium hydroxide Proper amount
Purified water To 100.0 g
A similar gel preparation was also produced using
recombinant CPB-I in place of CPB-1.
Example 3:
An ophthalmic ointment having the following composition
was produced according to a standard method.
(Composition)
CPB-I 1-100 mg
Purified lanolin 10.0 g
White petrolatum To 100.0 g
A similar ophthalmic ointment was also produced by
using recombinant CPB-I in place of CPB-1.
Example 4:
An ophthalmic solution having the following
composition was produced according to a standard method.
19
(Composition)
CPB-I 1-100 mg
10~ Benzalkonium chloride solution 0.05 ml
Isotonic phosphate buffer solution To 100.0 g
A similar ophthalmic solution was also produced by
using recombinant CPB-I in place of CPB-1.
INDUSTRIAL APPLICABILITY
CPB-I and recombinant CPB-I, which are active
ingredients in the therapeutic agents for skin or corneal
diseases according to the present invention, have the
excellent activities in promoting regeneration of
granulations of fibroblast, migration of corneal endothelial
and epithelial cells, etc., and lowering PKC activity.
Because these agents have an action mechanism different from
that of the conventional agent, they can be used together
with the conventional agent to enhance the therapeutic
effect.
Therefore, the therapeutic agents for skin or corneal
diseases according to the present invention are remarkably
useful for treating all sorts of the skin and corneal
diseases, in particular, wounds and psoriasis.
